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Dr Y. Joseph Woo (Philadelphia, Pa).You should be congratulated
for a fantastic study, particularly with the technical aspects that you
showed and also the creative water bath assay. You answered a lot of
the potential questions that the audience would have with in your
last two slides.
Your study is very good at showing the effects of your therapy.
To take your study to the next level, you should show some mech-
anistic components. The investigators who are doing a lot of the
stem cell transplantation work are thinking that there is not much
cross-linking of the cells and probably not a tremendous contractile
contribution from stem cell transplantation, but rather some sort of
biofactory effect. You did measure a multitude of different parame-
ters. Can you comment on some of the other things that you may be
in the process of measuring that would perhaps better elucidate the
mechanism in effect here?
Dr Molina. Thank you, Dr Woo, for your comments and ques-
tions. Regarding the mechanisms of action of bone marrow–derived
MSCs, I think that is one of the fundamental questions in this area of
research, as you mentioned. The contribution of MSCs to the im-
provement in contractile function of these hearts is probably mild.
Contractile function is improved in treated animals in comparison
with the control group at 21 and 28 days after therapy, but if we com-
pare treated animals with baseline contractility before cell transplan-
tation, it is probably similar. We think that both systolic and diastolic
function became stable after treatment. Treatment with bone mar-
row–derived MSCs, at least in this study, avoided the deterioration
in contractility that occurs with progression of heart failure. Whether
the cells really differentiate into cardiomyocytes is still unknown.
We are still running studies to identify these cells at later intervals,
and we are planning to do it with confocal microscopy. However,
there are other findings that I did not present that are also significant
in terms of alternative potential mechanisms of action. We have
measured tissue growth factors in these hearts, and several ofThe Journal of Thorthem are significantly increased in the cell treatment group: for
example, insulin-like growth factor, hepatocyte growth factor, and
platelet-derived growth factor. We think that the paracrine effects
that these cells exert on native cardiomyocytes might play a very
significant role in terms of the mechanisms of action.
Dr Beat H. Walpoth (Geneva, Switzerland). Although you
stated improvements in remodeling, function, and anti-inflamma-
tion, so far as I have seen, you have only shown one slide with
a few labeled cells at a very early time point after injection. Did
you find any surviving cells at 28 days and did you try to quantify
them? Additionally, differentiation and characterization of the in-
jected cells would be helpful to support your hemodynamic results.
Dr Molina. Thank you for your question. These cells were
marked not only with BrdU, as I showed in two slides, but also
with green fluorescent protein (GFP). Both of these markers tend
to disappear with cellular division. By Western blot analysis we
were able to find cells positive for GFP only up to 14 days after
cell injection. We did not find any GFP after that time interval. As
I mentioned before, we are still in the process of obtaining images
with confocal microscopy at later time intervals, which represents
a challenging task.
In our next studies we are planning to use GFP with a lentiviral
GFP adenovirus transfection, which is a much more stable transfec-
tion and is going to allow us to trace these cells for longer periods of
time.
Dr Mark J. Krasna (Baltimore, Md). Dr Molina, I have one
quick question. Technically, you were able to do two sternotomies
and a swim time. Did any of these rats die? In the manuscript it
appears that they all survived.
Dr Molina. Not all of them survived. In the first operation, aortic
clip placement, there was a survival of about 70%. About 15% of the
animals died during or right after the operation, usually of respira-
tory complications, and another 15% usually died during the
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